Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
Atish Mohanty, Arin Nam, Saumya Srivastava, et al.
Science Advances (2023) Vol. 9, Iss. 41
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Mı́riam Molina-Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 48
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
Changfeng Li, Yuanda Liu, Chang Liu, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 783
Closed Access | Times Cited: 3
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 12
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4189-4189
Open Access | Times Cited: 11
Unraveling the secrets: Evolution of resistance mediated by membrane proteins
Xue Yang, Min Li, Zi-Chang Jia, et al.
Drug Resistance Updates (2024) Vol. 77, pp. 101140-101140
Open Access | Times Cited: 10
Precision Oncology: 2023 in Review
Yonina R. Murciano‐Goroff, Sarah P. Suehnholz, Alexander Drilon, et al.
Cancer Discovery (2023) Vol. 13, Iss. 12, pp. 2525-2531
Open Access | Times Cited: 16
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Danielle Brazel, Misako Nagasaka
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 297-301
Open Access | Times Cited: 5
Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
Raquel Megid, Guilherme Ribeiro, Izabela Natália Faria Gomes, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
First molecules to reactivate RASG12V GTPase activity
Aneta Włodarczyk, Cezary Tręda, Marcin Pacholczyk, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer
Lin Bai, Xueqian Qian, Hui Zhang, et al.
Cell & Bioscience (2025) Vol. 15, Iss. 1
Open Access
Mesenchymal Stem Cell-Derived Exosomes in Cancer Resistance Against Therapeutics
Vignesh Balaji E, Keerthilatha M. Pai, K. Sreedhara Ranganath Pai
Cancers (2025) Vol. 17, Iss. 5, pp. 831-831
Open Access
Evaluation of the Inhibitory Potential of Apigenin and Related Flavonoids on Various Proteins Associated with Human Diseases Using AutoDock
Tanat Peanlikhit, Uma K. Aryal, James S. Welsh, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2548-2548
Open Access
Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models
Shihui Shen, Qiansen Zhang, Yuhan Wang, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 6
Open Access
New exploration of KRASG12D inhibitors and the mechanisms of resistance
Yinghong Li, Junfeng Zhao, Yintao Li
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications
Yoshinobu Kariya, Michiru Nishita
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3143-3143
Open Access
Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
H. Y. Shin, S. O. Hwang, Jeong Hyun Jeong, et al.
Pharmacological Research (2025), pp. 107722-107722
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Engineered protein circuits for cancer therapy
Andrew Lu, Lukas Moeller, Stephen T. Moore, et al.
(2025)
Open Access
Current perspectives of KRAS in non-small cell lung cancer
Ethan Harris, Rajat Thawani
Current Problems in Cancer (2024) Vol. 51, pp. 101106-101106
Closed Access | Times Cited: 3
Role of Wnt/β-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors
Charudatt Samant, Ramesh R. Kale, K. Sreedhara Ranganath Pai, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 729, pp. 150348-150348
Closed Access | Times Cited: 3
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer
Motohiro Izumi, Daniel B. Costa, Susumu Kobayashi
Lung Cancer (2024) Vol. 194, pp. 107885-107885
Closed Access | Times Cited: 3
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies
Atish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008505-e008505
Open Access | Times Cited: 3
ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure
Jamie Rijmers, Irene A. Retmana, Viët Bui, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116720-116720
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top